Cohance Lifesciences Limited has submitted a regulatory filing to the National Stock Exchange of India Limited and BSE Limited, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure informs that the United States Food and Drug Administration (USFDA) conducted an inspection of the Company's formulation (FDF) manufacturing plant. The plant is located at Shamshabad, Telangana.
The inspection period was from 27 August 2026 to 04 September 2026.
The inspection concluded with the USFDA issuing a Form FDA 483, which contained a total of four observations.
The Company states that it has initiated appropriate corrective and preventive actions (CAPA) in response to the observations. The Company will submit its formal response to the USFDA within the stipulated timeline.
The letter reiterates the Company's commitment to quality and regulatory compliance.
The disclosure was signed by Sisir K Mishra, Company Secretary and Compliance Officer, on 05 September 2026 at 00:27:29 IST.